ArticleBMC women's health2026
Discordant p53 and BRG1 expression in synchronous low-grade uterine endometrioid carcinoma and SMARCA4-deficient ovarian undifferentiated carcinoma: a case report.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSynchronous multiple primary malignancies (SMPMs) involving the uterus and ovary pose significant diagnostic challenges, particularly in distinguishing independent primary tumors from metastatic disease when tumors exhibit overlapping or divergent morphologic and molecular features. Accurate assessment of tumor clonality increasingly relies on integrated clinicopathologic and molecular profiling, which has important implications for staging, prognosis, and therapeutic decision-making. CASE PRESENTATION: We describe a 47-year-old woman presenting with abdominal distension and extensive peritoneal dissemination. Imaging revealed a uterine endometrial mass and bilateral adnexal lesions. Following neoadjuvant chemotherapy, she underwent optimal cytoreductive surgery. Histopathologic examination demonstrated a FIGO stage IA low-grade endometrioid carcinoma of the uterine corpus and a SMARCA4-deficient undifferentiated carcinoma of the ovary. Immunohistochemistry showed that the uterine tumor exhibited wild-type p53 expression, retained BRG1 expression, hormone receptor positivity, and proficient mismatch repair (pMMR) status. In contrast, the ovarian tumor demonstrated a p53-mutant phenotype with diffuse strong nuclear staining, complete loss of BRG1 expression, and pMMR status. Multiple foci of endometriosis were also identified in the pelvis.
conclusionsThe marked molecular heterogeneity observed in this case, particularly the discordant p53 and BRG1 expression patterns, supports the interpretation of two independent primary malignancies rather than metastatic spread from a common origin. This case highlights the value of integrated clinicopathologic and immunohistochemical assessment, including evaluation of p53, BRG1, and MMR status, in the diagnostic work-up of synchronous gynecologic tumors. Such an approach may contribute to more accurate diagnosis, risk stratification, and individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.